Dow Jones
39.164,06 +36,26 (+0,09%) Nasdaq
17.858,68 +53,53 (+0,30%) Nikkei 225
39.684,54 +343,00 (+0,87%) EUR/USD
1,0694 -0,0015 (-0,14%) Bitcoin EUR
57.721,62 +708,61 (+1,24%) CMC Crypto 200
1.280,58 +14,44 (+1,14%)
PRME Jul 2024 2.500 call
| Chiusura precedente | 2,7500 |
| Aperto | 2,7500 |
| Denaro | 2,4000 |
| Domanda | 6,0000 |
| Prezzo d'esercizio | 2,50 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 2,7500 - 2,7500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswirePrime Medicine to Present at Upcoming Investor Conferences
Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences: BMO Biopharma Virtual Spotlight Series: Latest Advances in Genome / Epigenome Editing: Fireside chat on Tuesday, September 26, 2023, at 10
- GlobeNewswire
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio’s shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBR
